Journal
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Volume 94, Issue -, Pages 251-263Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejpb.2015.05.023
Keywords
Influenza vaccines; Vaccine formulation; Vaccine production; Novel influenza vaccines; Influenza vaccine limitations; Universal influenza vaccine
Categories
Funding
- Center for Translational Molecular Medicine grant AMPVACS
Ask authors/readers for more resources
Vaccination is the most effective method to prevent influenza infection. However, current influenza vaccines have several limitations. Relatively long production times, limited vaccine capacity, moderate efficacy in certain populations and lack of cross-reactivity are important issues that need to be addressed. We give an overview of the current status and novel developments in the landscape of influenza vaccines from an interdisciplinary point of view. The feasibility of novel vaccine concepts not only depends on immunological or clinical outcomes, but also depends on biotechnological aspects, such as formulation and production methods, which are frequently overlooked. Furthermore, the next generation of influenza vaccines is addressed, which hopefully will bring cross-reactive influenza vaccines. These developments indicate that an exciting future lies ahead in the influenza vaccine field. (C) 2015 The Authors. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available